Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.55 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results